about
HTLV-1 tax specific CD8+ T cells express low levels of Tim-3 in HTLV-1 infection: implications for progression to neurological complicationsViral infections of the central nervous system: pathogenesis to therapeuticsHTLV-1, Immune Response and AutoimmunityTargeting the binding interface on a shared receptor subunit of a cytokine family enables the inhibition of multiple member cytokines with selectable target spectrum.CSF CXCL10, CXCL9, and neopterin as candidate prognostic biomarkers for HTLV-1-associated myelopathy/tropical spastic paraparesisGenes related to antiviral activity, cell migration, and lysis are differentially expressed in CD4(+) T cells in human t cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patients.HTLV-1 induces a Th1-like state in CD4+CCR4+ T cells.Evaluation of HTLV-1 activity in HAM/TSP patients using proviral load and Tax mRNA expression after In Vitro lymphocyte activation.Expansion in CD39⁺ CD4⁺ immunoregulatory t cells and rarity of Th17 cells in HTLV-1 infected patients is associated with neurological complications.HTLV-1 bZIP factor induces inflammation through labile Foxp3 expression.Minocycline modulates antigen-specific CTL activity through inactivation of mononuclear phagocytes in patients with HTLV-I associated neurologic disease.Localization, quantification and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATLQuantitative differences in HTLV-I antibody responses: classification and relative risk assessment for asymptomatic carriers and ATL and HAM/TSP patients from JamaicaIn contrast to HIV, KIR3DS1 does not influence outcome in HTLV-1 retroviral infectionHuman T-Lymphotropic Virus Type I (HTLV-1) Infection among Iranian Blood Donors: First Case-Control Study on the Risk FactorsHumoral immune response to HTLV-1 basic leucine zipper factor (HBZ) in HTLV-1-infected individualsLack of recall response to Tax in ATL and HAM/TSP patients but not in asymptomatic carriers of human T-cell leukemia virus type 1.Human T-lymphotropic Virus Type I (HTLV-I) Proviral Load and Clinical Features in Iranian HAM/TSP Patients: Comparison of HTLV-I Proviral Load in HAM/TSP Patients.Neuroimmunological aspects of human T cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis.Tax and Semaphorin 4D Released from Lymphocytes Infected with Human Lymphotropic Virus Type 1 and Their Effect on Neurite Growth.Positive feedback loop via astrocytes causes chronic inflammation in virus-associated myelopathy.Plasmatic proinflammatory chemokines levels are tricky markers to monitoring HTLV-1 carriers.Inhibition of cyclin-dependent kinase 5 but not of glycogen synthase kinase 3-β prevents neurite retraction and tau hyperphosphorylation caused by secretable products of human T-cell leukemia virus type I-infected lymphocytes.Long-term follow-up of HTLV-1 proviral load in asymptomatic carriers and in incident cases of HAM/TSP: what is its relevance as a prognostic marker for neurologic disease?Effects of host restriction factors and the HTLV-1 subtype on susceptibility to HTLV-1-associated myelopathy/tropical spastic paraparesisAltered expression of CXCR3 and CCR6 and their ligands in HTLV-1 carriers and HAM/TSP patients.Is there a role for ubiquitin or SUMO in human T-cell leukemia virus type 2 Tax-induced NF-κB activation?[Human retrovirus HTLV-1: descriptive and molecular epidemiology, origin, evolution, diagnosis and associated diseases].Role of HTLV-1 Tax and HBZ in the Pathogenesis of HAM/TSP.Brain white matter lesions in HAM/TSP: do they have any special meaning?
P2860
Q24607794-87A0C5AF-2431-4023-B6D2-347656FF1588Q26700069-4FD71683-A97D-4D8A-9847-4827A9C075A1Q26771801-D5FDFC36-5C4C-47DB-88C8-9C7855324DCEQ27312407-9F8E10E2-3CED-47CE-977B-920F00B54D1BQ28534309-9186E10E-41C8-4D52-8BFA-5BA8A014906AQ33713794-DD165FDA-B061-4CE2-B6A0-2A06A7B0CE76Q33944201-DFCC90F6-9162-48FD-AD89-04936B9D41BDQ34567129-38FE0A77-913F-4BD4-80A4-3C80E92EFFF2Q34587031-BE3D4B28-3A75-48CA-80AD-72E28ED70A76Q34998237-C0CC12A6-408C-4DB4-8EEB-1F3FCC664F5AQ35812057-F4D8A60E-2376-47F8-AC97-34E4291D2CC3Q35816954-12CD146F-3300-4EA1-B4E6-29A2B982B637Q35891629-47B93C9A-C921-45F9-BE25-5D0B6E3858BCQ36110061-8415AA5A-5CCC-4770-B137-16059BD015E7Q36333625-40FEDC41-DAD7-482E-995F-9C8C68AFC2EBQ36646919-E848C11D-38A4-462D-BD95-CD36DD7AE523Q37200968-7E020AFE-0308-4830-AB30-86B8F6905F39Q37435348-715732CF-DC84-40EA-B32F-3D1948C9A8A2Q38128799-49FFCE22-B8FE-41FA-B889-4755E3938DC1Q38833914-41AE3505-B9FD-4D18-B006-447F8964F981Q38874995-86ED7363-FBE4-4D37-97E6-4367B23096C7Q38940579-A3E2681E-264F-4136-BFB5-D882EC28831CQ39207637-063B65C9-7470-4108-A39A-156E7FFDFBD0Q39220045-61FDF504-2EE7-4967-9F6D-8E4763BF6DF4Q39311297-014E2460-52F2-4607-8DFF-E5FAD1397B82Q39377291-22F3D3C4-17C6-4D3F-B3B8-6F484487864EQ39408726-1FB61BB2-DDDB-4DA5-A816-1AB7A14D411CQ46373938-812894B8-4090-4059-A952-4F09E0A20F31Q47201640-7CED97A5-290D-4394-B88D-31222C2A13E0Q48563378-CC242107-7868-45C6-AEC4-41E954ADD962
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Neuroimmunity of HTLV-I Infection.
@en
Neuroimmunity of HTLV-I Infection.
@nl
type
label
Neuroimmunity of HTLV-I Infection.
@en
Neuroimmunity of HTLV-I Infection.
@nl
prefLabel
Neuroimmunity of HTLV-I Infection.
@en
Neuroimmunity of HTLV-I Infection.
@nl
P2093
P2860
P1476
Neuroimmunity of HTLV-I Infection.
@en
P2093
Eiji Matsuura
Steven Jacobson
Yoshihisa Yamano
P2860
P2888
P304
P356
10.1007/S11481-010-9216-9
P577
2010-05-02T00:00:00Z